CCR9 INHIBITORS AND METHODS OF USE THEREOF

摘要

The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.

主权项

1. A compound represented by the following structural formula (V): or a pharmaceutically acceptable salt thereof, wherein: X1, X2, and X3 are each independently N or CR, provided that at least one of X1, X2, or X3 is CR; X4 is CR, N or N+—O−; R, for each occurrence, is independently H, an aliphatic group, haloalkyl, aryl, arylalkyl, alkoxy, cycloalkoxy, haloalkoxy, aryloxy, arylalkoxy, alkylthio, halo, nitro, cyano, sulonamido, sulfone, sulfoxide, hydroxy, NR11CO2R12, C(O)N(R11)2, C(O)R12, CO2R12, OC(O)N(R11)2, OC(O)R12, N(R11)2, or NR11C(O)R12;
wherein R11, for each occurrence is, independently, H or an aliphatic group, and R12 is an aliphatic group; R1, R2, R3, R4 and R5 are each independently aliphatic group, haloalkyl, halo, COOH, NO2, alkoxy or haloalkoxy; and Ar2 is a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group.